MarginsXMarginsX
Home › Markets › Health Care › GERN

Geron Corporation (GERN)

GERN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.9419
-2.60% on the day
Market cap
$606.8M
Small cap
Revenue · 2023
$237K
-60.2% on 2022
Net income · 2023
-$184.1M
-77690.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/886744/000095017024022056/0000950170-24-022056-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.

Profile

FieldValue
TickerGERN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year1996
SEC CIK0000886744
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2023

LineValue
Revenue$237K
Net income-$184.1M
Operating income-$193.9M
Net margin-77690.7%
Operating margin-81832.9%
Revenue growth-60.2%
Cash$70.0M
Total assets$394.1M
P/E (computed)Net income was not positive
P/S (computed)2560.4×

Warning signs

Cash runway
9.2 months
$69.2M cash at September 30, 2026
Share count, 1 year
+0.9%
2025-11-04 to 2026-10-30 · +18.6% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$19K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$69.2M cash; operating cash flow -$22.6M a quarter.Report 2026-09-30
Shares outstanding644,238,859 (2026-10-30); 638,355,275 a year earlier; 543,063,950 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-03-02
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $19K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$60.2M$1.4M$10.3M$69.2M$120.4MNeeds four quarters10-Q 2026-11-04
Q2 2026
2026-06-30
$57.5M-$16.7M-$15.8M$62.6M$120.1MNeeds four quarters10-Q 2026-08-05
Q1 2026
2026-03-31
$51.8M-$3.6M-$62.9M$68.9M$119.8MNeeds four quarters10-Q 2026-05-06
Q4 2025
2025-12-31
Not filed-$28.9M-$22.1M$77.6M$119.5MNeeds four quarters10-K 2026-03-02
Q3 2025
2025-09-30
$47.2M-$18.4M-$13.6M$78.1M$119.3MNeeds four quarters10-Q 2026-11-04
Q2 2025
2025-06-30
$49.0M-$16.4M-$27.4M$77.7M$119.0MNeeds four quarters10-Q 2026-08-05
Q1 2025
2025-03-31
$39.6M-$19.8M-$48.0M$83.7M$118.7MNeeds four quarters10-Q 2026-05-06
Q4 2024
2024-12-31
Not filed-$25.4M-$43.9M$79.0M$118.5MNeeds four quarters10-K 2026-03-02

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-03-02
Latest annual report10-K2026-03-02
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-07

Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.0%
1 month-19.2%
3 months-37.0%
Year to date-26.5%
1 year-15.7%
From 52-week high-50.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AVBPArriVent BioPharma Inc.$11.56-11.15%$597.9M
ABUSArbutus Biopharma Corporation$4.04-1.22%$619.3M
IMMXImmix Biopharma Inc.$7.48-4.59%$626.9M
CLYMClimb Bio Inc.$9.94-4.05%$583.9M
DSGNDesign Therapeutics Inc.$9.92-5.25%$635.2M
ACRSAclaris Therapeutics Inc.$3.60-8.04%$571.8M
OLMAOlema Oncology Inc.$7.36-2.65%$644.8M
ANLAdlai Nortye Group Ltd.$10.03-5.47%$645.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier